Per Stirling Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Per Stirling Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-720	Closed	-$457K	–	286
2025 Q1	$457K	Hold	720	–	–	0.07%	173
2024 Q4	$513K	Sell	720 -3	-0.4%	-$2.52K	0.07%	159
2024 Q3	$760K	Sell	723 -7	-1%	-$7.79K	0.11%	134
2024 Q2	$767K	Hold	730	–	–	0.12%	118
2024 Q1	$702K	Hold	730	–	–	0.12%	114
2023 Q4	$641K	Hold	730	–	–	0.12%	107
2023 Q3	$600K	Sell	730 -5	-0.7%	-$3.93K	0.12%	105
2023 Q2	$528K	Sell	735 -28	-4%	-$21.6K	0.11%	116
2023 Q1	$627K	Sell	763 -150	-16%	-$113K	0.14%	93
2022 Q4	$659K	Buy	+913	New	+$674K	0.12%	103

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Per Stirling Capital Management's REGN Position: Q2 2025 in Review

Per Stirling Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 720 shares — an estimated $457K sold.

Per Stirling Capital Management first reported a position in REGN in Q4 2022 and held it in 10 quarters. The position peaked at $767K in Q2 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Per Stirling Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Per Stirling Capital Management sold 720 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $457K.
Per Stirling Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 10 quarters.
Per Stirling Capital Management's Regeneron Pharmaceuticals position peaked at $767K in Q2 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Per Stirling Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.